BioCryst Pharmaceuticals (NASDAQ: BCRX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
BioCryst Pharmaceuticals Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BioCryst Pharmaceuticals Company Info
A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.
News & Analysis
A day after the stock plummeted, it bounced back.
Investors didn't like the drugmaker's Q4 update.
BioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders.
The FDA has lifted the partial clinical hold on the biotech's kidney disease drug.
BioCryst Pharmaceuticals and Intellia Therapeutics could storm back in the second half of 2022.
The company receives some good news from a top regulator.
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.
The company gets a glowing green light from a foreign regulator for one of its pipeline drugs.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/22/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
BCRX earnings call for the period ending December 31, 2022.
BCRX earnings call for the period ending September 30, 2022.
BCRX earnings call for the period ending June 30, 2022.
BCRX earnings call for the period ending March 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.